Cipla USA, Inc. is voluntarily recalling approximately 15,221 pre-filled syringes of Lanreotide Injection (120 mg/0.5 mL) because particulate matter was found in the medication. Lanreotide is a prescription drug used for deep subcutaneous injection. This recall affects 32 specific lots distributed nationwide across the United States with expiration dates ranging from October 2026 to March 2027.
The presence of particulate matter in an injectable medication can cause local irritation or inflammation at the injection site. If the particles enter the bloodstream, they could potentially cause more serious complications such as damage to small blood vessels or vital organs.
You have 2 options:
Quantity: 15,221 syringes
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.